Evidence map›Paper›PMID 34262856›Full record

ArticleFrontiers in oncology2021

A Novel HAGE/WT1-ImmunoBody

Rukaia Almshayakhchi, Divya Nagarajan, Jayakumar Vadakekolathu, Barbara-Ann Guinn, Stephen Reeder, Victoria Brentville, Rachael Metheringham, A Graham Pockley, Lindy Durrant, Stephanie McArdle

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Rukaia AlmshayakhchiJohn van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.
Divya NagarajanJohn van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.
Jayakumar VadakekolathuJohn van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.
Barbara-Ann GuinnDepartment of Biomedical Sciences, University of Hull, Hull, United Kingdom.
Stephen ReederJohn van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.
Victoria BrentvilleScancell Ltd, Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom.
Rachael MetheringhamScancell Ltd, Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom.
A Graham PockleyJohn van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.
Lindy DurrantScancell Ltd, Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom.
Stephanie McArdleJohn van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.
Nottingham Trent University · GBUniversity of Nottingham · GBUniversity of Hull · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many cancers, including myeloid leukaemia express the cancer testis antigen (CTA) DDX43 (HAGE) and/or the oncogene Wilms' tumour (WT1). Here we demonstrate that HAGE/WT1-ImmunoBody

Indexed as

cancer vaccine combinationHAGEHHDII/DR1 miceImmunoBody®immunotherapyWT1

Identifiers

PMID34262856
PMCPMC8273701
OpenAlexW3173571879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.